Lexicon Pharmaceuticals (LXRX) 0.89 $LXRX
Lexicon To Present At The BIO CEO & Investor Conference
PR Newswire - Fri Feb 06, 3:05PM CST
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that Lexicon management will present at the BIO CEO & Investor Conference on Tuesday, February 10, 2015 at 8:00 AM EST in New York City. Lexicon management will provide an overview of Lexicon's clinical development programs and milestones.
LXRX: 0.89 (unch)
Global Diabetes, Metabolic Syndrome and Cardiovascular Disease Markets Overview 2014
M2 - Thu Feb 05, 3:00AM CST
Research and Markets (http://www.researchandmarkets.com/research/ltppcg/diabetes) has announced the addition of the "Global Diabetes, Metabolic Syndrome and Cardiovascular Disease Markets Overview 2014" report to their offering. Proactive strategies for prevention of the disease are being put in place by international health organizations such as the World Health Organization (WHO), as well as by the health departments of industrialized and developing countries, and even at the local level where food ingredients regulations are being passed. There has been a dramatic increase in the incidence of diabetes worldwide, which has been exacerbated by the growing obesity problem across the globe. Once thought of as primarily a childhood disease--sometimes referred to as juvenile diabetes, now mostly Type 1 diabetes--the obesity crisis linked to the adoption of a high-fat, high-carbohydrate, high-calorie American diet has resulted in skyrocketing rates of diabetes among adults across the world. To compound the global diabetes epidemic, health professionals are witnessing an alarming increase in inflammatory diseases resulting from adult onset (i.e., Type 2) diabetes. This phenomenon is referred to as "metabolic syndrome" where a confluence of inflammatory conditions occur along with the diabetes. As a result, growing evidence appears to show that metabolic syndrome makes the diabetic patient susceptible to degenerative health conditions such as cardiovascular disease, stroke and, now believed, Alzheimer's disease. As the diabetes epidemic escalates, a new sense of urgency has taken hold. This publication report charts the changing landscape of the global diabetic population and explores the added health concerns resulting from the metabolic syndrome phenomenon and one of its major risk factors: cardiovascular disease (CVD). Furthermore, this study evaluates widely-accepted therapeutic approaches to diabetes that are currently in use, while providing an in-depth analysis of emerging technologies that will be used to treat diabetes and other inflammatory diseases in the future. Key Topics Covered: 1. Overview 2. Introduction 3. Understanding the Metabolic Conditions Underlying and Associated with Diabetes 4. Pharmaceutical Industry and the Anti-Diabetes Market 5. Non-Insulin Anti-Diabetes Products 6. Insulin 7. Emerging Anti-Diabetes Technologies and Products 8. Diagnosing Diabetes Using In Vitro Laboratory Tests 9. Market Trends, Challenges and Strategic Options 10. Company Profiles Companies Mentioned: 30 of the 66 companies featured in this extensive report - Abbott Laboratories - Abbvie - Amgen - Animas (part of Johnson & Johnson) - Asante - Astellas Pharma, Inc. - AstraZeneca Plc - Bayer - Becton, Dickinson and Company - Boehringer Ingelheim - Bristol Myers Squibb - Daiichi Sankyo - DexCom - Echo Therapeutics, Inc. - Eli Lilly - Generex Biotechnology Corporation - GlaxoSmithKline Plc - Johnson & Johnson - Kowa Pharmaceuticals - Lexicon Pharmaceuticals - Medtronic - Merck & Company, Inc. - Mitsubishi Tanabe Pharma Corporation - Novartis - Novo Nordisk - Pfizer - Roche Diagnostics - Sanofi-Aventis - Taisho Pharmaceuticals - Takeda For more information visit http://www.researchandmarkets.com/research/ltppcg/diabetes
ABT: 46.09 (+0.87), MDT: 75.26 (+0.33), LXRX: 0.89 (unch), AMGN: 153.48 (+0.30), LLY: 70.56 (+0.03), GSK: 47.94 (+1.99), ECTE: 2.62 (+0.06), JNJ: 99.62 (+1.18), NVO: 43.76 (+0.61), AZN: 69.96 (+0.20), MRK: 58.81 (-0.07), NVS: 102.20 (-0.17)
Lexicon To Present At The 33rd Annual J.P. Morgan Healthcare Conference
PR Newswire - Wed Jan 07, 3:30PM CST
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that Lexicon management will present at the 33rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2015 at 4:30 PM PST in San Francisco. Lexicon management will provide an overview of Lexicon's clinical development programs and milestones.
JPM: 59.67 (+0.10), LXRX: 0.89 (unch)
Lexicon (LXRX): Strong Industry, Solid Earnings Estimate Revisions - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Dec 23, 7:48AM CST
Lexicon has been witnessing a positive trend in its current year loss estimates and possess a favorable Zacks Industry Rank
LXRX: 0.89 (unch)
Lexicon Pharmaceuticals (LXRX): Strong Industry, Solid Earnings Estimate Revisions - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Dec 15, 8:01AM CST
Lexicon Pharmaceuticals is seeing solid earnings estimate revision activity and is in great company from a Zacks Industry Rank perspective
LXRX: 0.89 (unch)
Lexicon To Present At The Oppenheimer 25th Annual Healthcare Conference
PR Newswire - Mon Dec 08, 5:02PM CST
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that Lexicon management will present at the Oppenheimer 25th Annual Healthcare Conference on Wednesday, December 10, 2014 at 4:30 PM EST in New York City. Lexicon management will provide an overview of Lexicon's clinical development programs and milestones.
LXRX: 0.89 (unch)
Arthritis - Pipeline Review, H2 2014
M2 - Mon Dec 08, 3:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/42nbjz/arthritis) has announced the addition of the "Arthritis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Arthritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Arthritis and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Arthritis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Arthritis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Eli Lilly and Company - GlaxoSmithKline - Nemucore Medical Innovations - Taisho Pharmaceutical - Sylentis - Astellas Pharma - Eisai - Bone Medical - Momenta Pharmaceuticals - Can-Fite BioPharma - Lexicon Pharmaceuticals - CSL Limited - WhanIn Pharmaceutical - Oscotec Inc. - Viron Therapeutics - PLx Pharma - Endocyte - Cardax Pharmaceuticals - Taiwan Liposome Company - NasVax - CalciMedica - Zyngenia - SelectX Pharmaceuticals - DoNatur - CellAct Pharma - Arcarios - Inbiopro Solutions - Sagene Pharmaceuticals - vida therapeutics - Dong-A Socio For more information visit http://www.researchandmarkets.com/research/42nbjz/arthritis
CANF: 3.85 (+0.05), LXRX: 0.89 (unch), LLY: 70.56 (+0.03), GSK: 47.94 (+1.99), MNTA: 11.70 (-0.06)
Lexicon concludes USD280m in concurrent financing transactions
M2 - Fri Nov 28, 3:01AM CST
Biopharmaceutical company Lexicon Pharmaceuticals (NasdaqGS:LXRX) disclosed on Thursday the completion of the concurrent transactions for gross proceeds of USD280.0m.
LXRX: 0.89 (unch)
InsiderInsights.com Daily Round Up 11/26/14: VRX, INTX, AEHR, HRG
InsiderInsights - at Seeking Alpha - Wed Nov 26, 11:53PM CST
SC: 22.11 (+0.38), VRX: 167.00 (-0.50), LXRX: 0.89 (unch), NEOT: 6.69 (-0.04), AEHR: 2.47 (+0.01), BBY: 39.11 (-0.08), SGM: 10.68 (+0.08), FIVE: 33.01 (+0.11), INTX: 3.73 (+0.19), SPW: 87.37 (-2.81), REXX: 5.08 (+0.13), HRG: 11.84 (-0.06), PF: 36.18 (-0.21), PGRE: 18.54 (-0.11), AAPL: 127.08 (+0.62), INTU: 90.25 (+0.86), CSCO: 29.43 (-0.03), KPTI: 27.12 (-0.13)
Lexicon Announces Completion Of $280 Million In Financing Transactions
PR Newswire - Wed Nov 26, 3:01PM CST
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the completion of previously announced concurrent financing transactions resulting in gross proceeds of $280.0 million. After fees and estimated offering expenses, Lexicon anticipates net proceeds of approximately $273.7 million from the transactions. The transactions consisted of:
LXRX: 0.89 (unch)
A Change In Strategy: Lexicon Pharmaceuticals
Samuel Riehn - at Seeking Alpha - Sun Nov 23, 11:04PM CST
LXRX: 0.89 (unch)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Nov 21, 11:46AM CST
LEJU: 10.88 (+0.48), GEOS: 19.15 (+0.02), LXRX: 0.89 (unch), OTIV: 1.75 (unch), GME: 37.35 (+0.10), ARUN: 17.70 (-0.01), NBS: 3.78 (+0.14), PHMD: 1.68 (+0.04), AMDA: 0.65 (+0.01), CANF: 3.85 (+0.05), MOLG: 2.46 (+0.03), WAIR: 14.32 (+0.30), EDAP: 3.55 (+0.13), FWM: 5.55 (+0.08), GERN: 3.03 (unch), OCRX: 6.27 (-0.16), NGVC: 30.28 (+0.45), SFUN: 6.74 (-0.01), EJ: 7.44 (+0.01), BGI: 1.41 (-0.05)
Lexicon Pharmaceuticals Fights On
Stephen Simpson, CFA - at Seeking Alpha - Fri Nov 21, 11:09AM CST
LXRX: 0.89 (unch)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Fri Nov 21, 8:13AM CST
NETE: 1.29 (+0.14), ANV: 0.97 (-0.03), EXXI: 4.00 (+0.42), LXRX: 0.89 (unch), OTIV: 1.75 (unch), GME: 37.35 (+0.10), ARUN: 17.70 (-0.01), GFI: 4.83 (-0.21), CLF: 7.00 (+0.35), NYMT: 7.75 (+0.05), AMDA: 0.65 (+0.01), MOLG: 2.46 (+0.03), SID: 1.76 (+0.06), SCTY: 57.60 (+0.44), VALE: 8.05 (+0.32), SFUN: 6.74 (-0.01), GOL: 3.85 (+0.01), SPLK: 64.18 (+2.25), ICLD: 2.87 (+0.11), BBL: 48.82 (+2.36), ROST: 96.18 (+0.51)
How To Be Smarter About Risk Management
Morningstar - Seeking Alpha - Fri Nov 21, 7:00AM CST
By Alex Bryan Note: This article is part of Morningstar's November 2014 Risk Management Week special report. An earlier version appeared Aug. 13, 2014. In isolation, risk is neither good nor bad. Finance 101 teaches that the market must offer...
MMM: 165.94 (+0.03), SPY: 209.78 (+0.86), SPLV: 38.18 (-0.27), LXRX: 0.89 (unch), QUAL: 63.94 (+0.39), USMV: 41.48 (+0.03)
Lexicon prices public offering at USD1.005 per share
M2 - Fri Nov 21, 6:05AM CST
Biopharmaceutical company Lexicon Pharmaceuticals (NasdaqGS:LXRX) said on Thursday that it has priced a public offering of USD50m shares of its common stock.
LXRX: 0.89 (unch)
Lexicon Announces Pricing Of Convertible Senior Notes Offering
PR Newswire - Fri Nov 21, 12:00AM CST
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it has priced its offering of $80,000,000 aggregate principal amount of 5.25% Convertible Senior Notes due 2021 (the "Convertible Notes"
in a private offering within the United States. The Convertible Notes were offered to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act" . Lexicon has also granted the initial purchasers an option to purchase up to an additional $15,000,000 aggregate principal amount of the Convertible Notes on the same terms and conditions, solely to cover over-allotments. Lexicon expects to close the offering on November 26, 2014, subject to the satisfaction of customary closing conditions.
LXRX: 0.89 (unch)
Lexicon Announces Pricing Of Common Stock Offering
PR Newswire - Fri Nov 21, 12:00AM CST
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the pricing of its previously announced underwritten public offering of $50,000,000 of shares of its common stock pursuant to an effective shelf registration statement. The offering will consist of 49,751,244 shares of common stock at a public offering price of $1.005 per share. Lexicon has also granted the underwriters a 30-day option to purchase up to 7,462,687 additional shares of common stock. All of the shares in the offering will be sold by Lexicon. J.P. Morgan Securities, LLC and Goldman, Sachs & Co. are acting as joint book-runners for the offering and Needham & Company, LLC and Stifel, Nicolaus & Company, Incorporated are acting as co-managers for the offering. Lexicon expects to close the offering on November 26, 2014, subject to the satisfaction of customary closing conditions.
JPM: 59.67 (+0.10), LXRX: 0.89 (unch)
Lexicon drops on dilutive stock offering
Seeking Alpha - at Seeking Alpha - Thu Nov 20, 11:35AM CST
LXRX: 0.89 (unch)
Lexicon To Present At The BIO CEO & Investor Conference
PR Newswire - Fri Feb 06, 3:05PM CST
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that Lexicon management will present at the BIO CEO & Investor Conference on Tuesday, February 10, 2015 at 8:00 AM EST in New York City. Lexicon management will provide an overview of Lexicon's clinical development programs and milestones.
LXRX: 0.89 (unch)
Global Diabetes, Metabolic Syndrome and Cardiovascular Disease Markets Overview 2014
M2 - Thu Feb 05, 3:00AM CST
Research and Markets (http://www.researchandmarkets.com/research/ltppcg/diabetes) has announced the addition of the "Global Diabetes, Metabolic Syndrome and Cardiovascular Disease Markets Overview 2014" report to their offering. Proactive strategies for prevention of the disease are being put in place by international health organizations such as the World Health Organization (WHO), as well as by the health departments of industrialized and developing countries, and even at the local level where food ingredients regulations are being passed. There has been a dramatic increase in the incidence of diabetes worldwide, which has been exacerbated by the growing obesity problem across the globe. Once thought of as primarily a childhood disease--sometimes referred to as juvenile diabetes, now mostly Type 1 diabetes--the obesity crisis linked to the adoption of a high-fat, high-carbohydrate, high-calorie American diet has resulted in skyrocketing rates of diabetes among adults across the world. To compound the global diabetes epidemic, health professionals are witnessing an alarming increase in inflammatory diseases resulting from adult onset (i.e., Type 2) diabetes. This phenomenon is referred to as "metabolic syndrome" where a confluence of inflammatory conditions occur along with the diabetes. As a result, growing evidence appears to show that metabolic syndrome makes the diabetic patient susceptible to degenerative health conditions such as cardiovascular disease, stroke and, now believed, Alzheimer's disease. As the diabetes epidemic escalates, a new sense of urgency has taken hold. This publication report charts the changing landscape of the global diabetic population and explores the added health concerns resulting from the metabolic syndrome phenomenon and one of its major risk factors: cardiovascular disease (CVD). Furthermore, this study evaluates widely-accepted therapeutic approaches to diabetes that are currently in use, while providing an in-depth analysis of emerging technologies that will be used to treat diabetes and other inflammatory diseases in the future. Key Topics Covered: 1. Overview 2. Introduction 3. Understanding the Metabolic Conditions Underlying and Associated with Diabetes 4. Pharmaceutical Industry and the Anti-Diabetes Market 5. Non-Insulin Anti-Diabetes Products 6. Insulin 7. Emerging Anti-Diabetes Technologies and Products 8. Diagnosing Diabetes Using In Vitro Laboratory Tests 9. Market Trends, Challenges and Strategic Options 10. Company Profiles Companies Mentioned: 30 of the 66 companies featured in this extensive report - Abbott Laboratories - Abbvie - Amgen - Animas (part of Johnson & Johnson) - Asante - Astellas Pharma, Inc. - AstraZeneca Plc - Bayer - Becton, Dickinson and Company - Boehringer Ingelheim - Bristol Myers Squibb - Daiichi Sankyo - DexCom - Echo Therapeutics, Inc. - Eli Lilly - Generex Biotechnology Corporation - GlaxoSmithKline Plc - Johnson & Johnson - Kowa Pharmaceuticals - Lexicon Pharmaceuticals - Medtronic - Merck & Company, Inc. - Mitsubishi Tanabe Pharma Corporation - Novartis - Novo Nordisk - Pfizer - Roche Diagnostics - Sanofi-Aventis - Taisho Pharmaceuticals - Takeda For more information visit http://www.researchandmarkets.com/research/ltppcg/diabetes
ABT: 46.09 (+0.87), MDT: 75.26 (+0.33), LXRX: 0.89 (unch), AMGN: 153.48 (+0.30), LLY: 70.56 (+0.03), GSK: 47.94 (+1.99), ECTE: 2.62 (+0.06), JNJ: 99.62 (+1.18), NVO: 43.76 (+0.61), AZN: 69.96 (+0.20), MRK: 58.81 (-0.07), NVS: 102.20 (-0.17)
Lexicon To Present At The 33rd Annual J.P. Morgan Healthcare Conference
PR Newswire - Wed Jan 07, 3:30PM CST
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that Lexicon management will present at the 33rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2015 at 4:30 PM PST in San Francisco. Lexicon management will provide an overview of Lexicon's clinical development programs and milestones.
JPM: 59.67 (+0.10), LXRX: 0.89 (unch)
Lexicon (LXRX): Strong Industry, Solid Earnings Estimate Revisions - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Dec 23, 7:48AM CST
Lexicon has been witnessing a positive trend in its current year loss estimates and possess a favorable Zacks Industry Rank
LXRX: 0.89 (unch)
Lexicon Pharmaceuticals (LXRX): Strong Industry, Solid Earnings Estimate Revisions - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Dec 15, 8:01AM CST
Lexicon Pharmaceuticals is seeing solid earnings estimate revision activity and is in great company from a Zacks Industry Rank perspective
LXRX: 0.89 (unch)
Lexicon To Present At The Oppenheimer 25th Annual Healthcare Conference
PR Newswire - Mon Dec 08, 5:02PM CST
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that Lexicon management will present at the Oppenheimer 25th Annual Healthcare Conference on Wednesday, December 10, 2014 at 4:30 PM EST in New York City. Lexicon management will provide an overview of Lexicon's clinical development programs and milestones.
LXRX: 0.89 (unch)
Arthritis - Pipeline Review, H2 2014
M2 - Mon Dec 08, 3:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/42nbjz/arthritis) has announced the addition of the "Arthritis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Arthritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Arthritis and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Arthritis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Arthritis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Eli Lilly and Company - GlaxoSmithKline - Nemucore Medical Innovations - Taisho Pharmaceutical - Sylentis - Astellas Pharma - Eisai - Bone Medical - Momenta Pharmaceuticals - Can-Fite BioPharma - Lexicon Pharmaceuticals - CSL Limited - WhanIn Pharmaceutical - Oscotec Inc. - Viron Therapeutics - PLx Pharma - Endocyte - Cardax Pharmaceuticals - Taiwan Liposome Company - NasVax - CalciMedica - Zyngenia - SelectX Pharmaceuticals - DoNatur - CellAct Pharma - Arcarios - Inbiopro Solutions - Sagene Pharmaceuticals - vida therapeutics - Dong-A Socio For more information visit http://www.researchandmarkets.com/research/42nbjz/arthritis
CANF: 3.85 (+0.05), LXRX: 0.89 (unch), LLY: 70.56 (+0.03), GSK: 47.94 (+1.99), MNTA: 11.70 (-0.06)
Lexicon concludes USD280m in concurrent financing transactions
M2 - Fri Nov 28, 3:01AM CST
Biopharmaceutical company Lexicon Pharmaceuticals (NasdaqGS:LXRX) disclosed on Thursday the completion of the concurrent transactions for gross proceeds of USD280.0m.
LXRX: 0.89 (unch)
InsiderInsights.com Daily Round Up 11/26/14: VRX, INTX, AEHR, HRG
InsiderInsights - at Seeking Alpha - Wed Nov 26, 11:53PM CST
SC: 22.11 (+0.38), VRX: 167.00 (-0.50), LXRX: 0.89 (unch), NEOT: 6.69 (-0.04), AEHR: 2.47 (+0.01), BBY: 39.11 (-0.08), SGM: 10.68 (+0.08), FIVE: 33.01 (+0.11), INTX: 3.73 (+0.19), SPW: 87.37 (-2.81), REXX: 5.08 (+0.13), HRG: 11.84 (-0.06), PF: 36.18 (-0.21), PGRE: 18.54 (-0.11), AAPL: 127.08 (+0.62), INTU: 90.25 (+0.86), CSCO: 29.43 (-0.03), KPTI: 27.12 (-0.13)
Lexicon Announces Completion Of $280 Million In Financing Transactions
PR Newswire - Wed Nov 26, 3:01PM CST
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the completion of previously announced concurrent financing transactions resulting in gross proceeds of $280.0 million. After fees and estimated offering expenses, Lexicon anticipates net proceeds of approximately $273.7 million from the transactions. The transactions consisted of:
LXRX: 0.89 (unch)
A Change In Strategy: Lexicon Pharmaceuticals
Samuel Riehn - at Seeking Alpha - Sun Nov 23, 11:04PM CST
LXRX: 0.89 (unch)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Nov 21, 11:46AM CST
LEJU: 10.88 (+0.48), GEOS: 19.15 (+0.02), LXRX: 0.89 (unch), OTIV: 1.75 (unch), GME: 37.35 (+0.10), ARUN: 17.70 (-0.01), NBS: 3.78 (+0.14), PHMD: 1.68 (+0.04), AMDA: 0.65 (+0.01), CANF: 3.85 (+0.05), MOLG: 2.46 (+0.03), WAIR: 14.32 (+0.30), EDAP: 3.55 (+0.13), FWM: 5.55 (+0.08), GERN: 3.03 (unch), OCRX: 6.27 (-0.16), NGVC: 30.28 (+0.45), SFUN: 6.74 (-0.01), EJ: 7.44 (+0.01), BGI: 1.41 (-0.05)
Lexicon Pharmaceuticals Fights On
Stephen Simpson, CFA - at Seeking Alpha - Fri Nov 21, 11:09AM CST
LXRX: 0.89 (unch)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Fri Nov 21, 8:13AM CST
NETE: 1.29 (+0.14), ANV: 0.97 (-0.03), EXXI: 4.00 (+0.42), LXRX: 0.89 (unch), OTIV: 1.75 (unch), GME: 37.35 (+0.10), ARUN: 17.70 (-0.01), GFI: 4.83 (-0.21), CLF: 7.00 (+0.35), NYMT: 7.75 (+0.05), AMDA: 0.65 (+0.01), MOLG: 2.46 (+0.03), SID: 1.76 (+0.06), SCTY: 57.60 (+0.44), VALE: 8.05 (+0.32), SFUN: 6.74 (-0.01), GOL: 3.85 (+0.01), SPLK: 64.18 (+2.25), ICLD: 2.87 (+0.11), BBL: 48.82 (+2.36), ROST: 96.18 (+0.51)
How To Be Smarter About Risk Management
Morningstar - Seeking Alpha - Fri Nov 21, 7:00AM CST
By Alex Bryan Note: This article is part of Morningstar's November 2014 Risk Management Week special report. An earlier version appeared Aug. 13, 2014. In isolation, risk is neither good nor bad. Finance 101 teaches that the market must offer...
MMM: 165.94 (+0.03), SPY: 209.78 (+0.86), SPLV: 38.18 (-0.27), LXRX: 0.89 (unch), QUAL: 63.94 (+0.39), USMV: 41.48 (+0.03)
Lexicon prices public offering at USD1.005 per share
M2 - Fri Nov 21, 6:05AM CST
Biopharmaceutical company Lexicon Pharmaceuticals (NasdaqGS:LXRX) said on Thursday that it has priced a public offering of USD50m shares of its common stock.
LXRX: 0.89 (unch)
Lexicon Announces Pricing Of Convertible Senior Notes Offering
PR Newswire - Fri Nov 21, 12:00AM CST
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it has priced its offering of $80,000,000 aggregate principal amount of 5.25% Convertible Senior Notes due 2021 (the "Convertible Notes"
in a private offering within the United States. The Convertible Notes were offered to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act" . Lexicon has also granted the initial purchasers an option to purchase up to an additional $15,000,000 aggregate principal amount of the Convertible Notes on the same terms and conditions, solely to cover over-allotments. Lexicon expects to close the offering on November 26, 2014, subject to the satisfaction of customary closing conditions. LXRX: 0.89 (unch)
Lexicon Announces Pricing Of Common Stock Offering
PR Newswire - Fri Nov 21, 12:00AM CST
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the pricing of its previously announced underwritten public offering of $50,000,000 of shares of its common stock pursuant to an effective shelf registration statement. The offering will consist of 49,751,244 shares of common stock at a public offering price of $1.005 per share. Lexicon has also granted the underwriters a 30-day option to purchase up to 7,462,687 additional shares of common stock. All of the shares in the offering will be sold by Lexicon. J.P. Morgan Securities, LLC and Goldman, Sachs & Co. are acting as joint book-runners for the offering and Needham & Company, LLC and Stifel, Nicolaus & Company, Incorporated are acting as co-managers for the offering. Lexicon expects to close the offering on November 26, 2014, subject to the satisfaction of customary closing conditions.
JPM: 59.67 (+0.10), LXRX: 0.89 (unch)
Lexicon drops on dilutive stock offering
Seeking Alpha - at Seeking Alpha - Thu Nov 20, 11:35AM CST
LXRX: 0.89 (unch)
